| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
Form 4: Arcara Jeffrey, Chief Business Officer
Bought 3,000 shares ($34.4K) · Bought 497 shares ($5.52K) · Bought 1,003 shares ($10.6K) |
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track |
| 27 Jul 2026 | SCHEDULE 13G/A |
| 22 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 15 Jun 2026 |
Form 4: Moore David Scott, Director
Bought 21,700 shares ($250K) · Granted 15,000 Stock Option (Right to Buy) |
| 15 Jun 2026 |
Form 4: Clark Ian T, Director
Granted 15,000 Stock Option (Right to Buy) |
| 15 Jun 2026 |
Form 4: Grais Linda, Director
Granted 15,000 Stock Option (Right to Buy) |
| 15 Jun 2026 |
Form 4: Thompson Peter A., Director
Granted 15,000 Stock Option (Right to Buy) |
| 15 Jun 2026 |
Form 4: van den Broek Richard, Director
Granted 15,000 Stock Option (Right to Buy) |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Corvus Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Only stockholders of record at the close of business on April 16, 2026, the record date for the Annual Me... |
| 20 May 2026 |
Form 4: Miller Richard A Md, Director
Bought 6,932 shares ($83.5K) |
| 15 May 2026 | SCHEDULE 13G/A |
| 15 May 2026 | SCHEDULE 13G |
| 14 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting |
| 07 May 2026 | FORM S-8 |
Loading...